Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ALAUNOS THERAPEUTICS INC (TCRT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.84+2.22%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TCRT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Resolve disputes with MD Anderson Cancer Center | Alaunos aims to maintain Nasdaq listing compliance and resolve disputes with MD Anderson. | Recovered | Disputes remain unresolved beyond next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making biotechnology company, not a proven compounder. The long-term thesis is in a watch state: financing supports a newly expanded focus on the Velaris pulmonary hypertension pipeline, but clinical delivery is not yet demonstrated in the supplied evidence.
The valuation is described as expensive versus peers, with a 24.32% premium and low model confidence. The evidence points to expectations tied to pipeline optionality, while weak execution quality and fragility make those expectations difficult to assess.
Recent results were neutral, but operating losses continued in both reported 2026 quarters, and the company reported no revenue in the supplied evidence. The October private placement provides financing for pipeline work, while an elevated near-term earnings-miss risk and two recent delisting-related notices remain concerns.
Over the multi-year view, the thesis depends on whether Velaris advances beyond a stated priority and whether ALN1003 produces further documented development progress. Near term, continued weakness in jobs data could weigh on cyclical healthcare names, while results and guidance from sector bellwethers could support or weaken the sector backdrop.
The 1-to-3-year view remains uncertain: new financing supports development, but losses, limited documented pipeline progress, weak execution signals, and listing notices keep risk high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Alaunos aims to maintain Nasdaq listing compliance and resolve disputes with MD Anderson. |
| Under Pressure |
| Nasdaq delisting or failure to satisfy listing rules |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Engage in strategic partnerships | The company has a market cap of $5M and is working on strategic partnerships. | Under Pressure | No strategic partnership engagement within next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-18.00 → $-18.00 · observed estimates
$0.22B → $0.22B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-07-25 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-07-26 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-07-27 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-07-28 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-07-29 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-07-30 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-07-31 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-01 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-02 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-03 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-04 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-05 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-06 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-08 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-09 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-10 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-12 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-13 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-14 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-15 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-16 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-17 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-18 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-19 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-20 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-21 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-22 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-23 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-24 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-25 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-26 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-27 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-28 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-29 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-30 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-08-31 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-01 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-02 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-03 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-04 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-05 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-06 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-07 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-08 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-09 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-10 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-11 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-12 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-13 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-14 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-15 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-16 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-17 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-18 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-19 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-20 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-21 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-22 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-23 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-24 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-25 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-26 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-27 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-28 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-29 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-09-30 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-01 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-02 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-03 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-04 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-05 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-06 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-07 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-08 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-09 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-10 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-11 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-12 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-13 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-14 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-15 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-16 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-17 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-18 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-19 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-20 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-21 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-22 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-23 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-24 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-25 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-26 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-27 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-28 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-29 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-30 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-10-31 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-11-01 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-11-02 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-11-03 | $-18.00 | $220,411,000 | 1 / 1 |
| 2026-11-04 | $-18.00 | $220,411,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.